San Diego-dependent Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug market in February immediately after revealing promising facts from the mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given to be a weekly injection and in March the… Read More